_Note: This article is a news-style briefing based on the prompt and summarizes the 2026 WHO guidance as described. Readers should consult their national health authorities or the WHO website for verified, up-to-date information._
# WHO Issues 2026 Guidance Recommending Annual RSV Booster for Over-65s — What Seniors and Care Homes Need to Know
The World Health Organization (WHO) has issued 2026 guidance recommending an annual respiratory syncytial virus (RSV) booster for people aged 65 and older. The move is aimed at reducing hospitalizations and severe respiratory illness among older adults, a population shown to be particularly vulnerable to RSV complications.
## Quick summary
– WHO recommends an annual RSV booster for adults aged 65+.
– Guidance emphasizes protection for residents of long-term care facilities and other high-risk groups.
– National health agencies will adapt the recommendation to local epidemiology, vaccine availability and health system capacity.
## Why this matters: RSV and older adults
RSV is commonly associated with infant illness, but it is also a significant cause of severe respiratory disease in older adults and people with chronic health conditions. For seniors, RSV can trigger exacerbations of chronic obstructive pulmonary disease (COPD), heart failure and other comorbidities, sometimes leading to hospitalization or death. The WHO guidance frames annual boosting as a public-health strategy to reduce that burden as RSV becomes an increasingly recognized seasonal threat in older populations.
## What the WHO guidance says (high-level)
According to the 2026 guidance summary, WHO recommends that countries consider offering an annual RSV booster to adults aged 65 years and older. The guidance:
– Prioritizes people living in long-term care facilities, nursing homes and other congregate settings.
– Encourages alignment of RSV booster programs with existing adult vaccination campaigns to simplify delivery.
– Advises national authorities to weigh local RSV seasonality, vaccine supply and infrastructure when planning rollouts.
The guidance also stresses ongoing monitoring of vaccine effectiveness and safety, and encourages countries to collect data that will help refine future recommendations.
## What seniors should know and do
– Talk to your healthcare provider: If you are 65 or older, discuss whether you should receive the RSV booster based on your health status and local recommendations.
– Watch for official roll-out dates: National and regional health agencies will publish schedules and locations for vaccination clinics.
– Continue standard precautions: Vaccination complements — but does not replace — measures such as good hand hygiene, staying home when ill and following care-home infection-control policies.
An illustrative scenario: Many care-home residents receive seasonal vaccines on-site. For seniors and caregivers, combining RSV boosters with regular vaccination visits may reduce missed opportunities and improve coverage.
## What care homes and long-term care facilities need to do
Care homes are highlighted in the guidance as priority settings. Administrators and clinical leads should:
– Coordinate with local public-health authorities to secure vaccine supply and schedule on-site clinics.
– Review consent procedures and documentation for booster administration.
– Update infection prevention policies to coincide with vaccination campaigns, including staff vaccination strategies to reduce transmission.
– Communicate clearly with residents and families about benefits, likely side effects and logistics.
Implementing an annual booster in congregate settings may also reduce disruptions caused by outbreaks, such as temporary visitor restrictions and staff shortages.
## Safety, side effects and monitoring
WHO’s guidance underscores safety monitoring. Common side effects for RSV vaccines and boosters tend to be similar to other adult vaccines — injection-site pain, fatigue and mild systemic symptoms — while serious adverse events are rare. The guidance calls for active surveillance systems to detect and investigate any safety signals rapidly.
If you or a resident experience concerning symptoms after vaccination, seek medical advice and report events to local health authorities.
## Access, equity and costs
WHO’s recommendation is intended to inform national policy; rollout will depend on country-level decisions, vaccine supply, reimbursement mechanisms and prioritization. Low- and middle-income countries may receive additional support from international programs and partnerships to expand access, and WHO encourages strategies that promote equitable distribution across populations and settings.
## Next steps for readers
– Check with your national public-health agency or primary care provider for official local recommendations and clinic locations.
– Care-home leaders should contact regional health authorities to plan onsite vaccination and staff training.
– Stay informed about safety monitoring and evolving evidence as programs are implemented.
As countries adapt the 2026 WHO guidance to their settings, seniors, families and care providers can expect more coordinated efforts to prevent RSV-related illness among older adults. For authoritative updates, consult your national health service and the World Health Organization’s official communications.
